Current Infectious Disease Reports

, Volume 12, Issue 6, pp 465–470 | Cite as

Vulvovaginal Candidiasis Caused by Non-albicans Candida Species: New Insights

  • Melissa A. Kennedy
  • Jack D. SobelEmail author


Non-albicans Candida species have increasingly been identified as the cause of vulvovaginitis. In vitro and in vivo data indicate that the various non-albicans Candida species identified in the lower genital tract differ considerably with regard to epidemiology, virulence or vaginal pathogenicity, and antimycotic drug susceptibility. Clinical experience indicates reduced virulence of these organisms in the lower genital tract, and their causal role in a symptomatic patient requires careful case-by-case determination rather than routine administration of antimycotic therapy. Accordingly, vaginal Candida isolates deserve species identification and consideration of pathogenic potential and antifungal susceptibility before therapeutic decisions are made.


Vaginitis Vulvovaginal candidiasis Candida species Candida albicans Non-albicans Candida Candida glabrata Candida parapsilosis 



No potential conflict of interest relevant to this article was reported.


Papers of particular interest, published recently, have been highlighted as: • Of importance

  1. 1.
    • Sobel JD: Vulvovaginal candidosis. Lancet 2007, 369:1961–71. This article provides an extensive review of the epidemiology, diagnosis, and treatment of vaginal Candida infection. CrossRefPubMedGoogle Scholar
  2. 2.
    Vermitsky JP, Self MJ, Chadwick SG, et al.: Survey of vaginal-flora Candida species isolates from women of different age groups by use of species-specific PCR detection. J Clin Microbiol 2008, 46: 1501–1503.CrossRefPubMedGoogle Scholar
  3. 3.
    Mohanty S, Xess I, Hasan F, et al.: Prevalence and susceptibility to fluconazole of Candida species causing vulvovaginitis. Indian J Med Res 2007, 126:216–219.PubMedGoogle Scholar
  4. 4.
    Grigoriou O, Baka S, Makrakis E, et al.: Prevalence of clinical vaginal candidiasis in a university hospital and possible risk factors. Eur J Obstet Gynecol Reprod Biol 2006, 126:121–125.CrossRefPubMedGoogle Scholar
  5. 5.
    Spinillo A, Capuzzo E, Gulminetti R, et al.: Prevalence of and risk factors for fungal vaginitis caused by non-albicans species. Am J Obstet Gynecol 1997, 176:138–141.CrossRefPubMedGoogle Scholar
  6. 6.
    Fan SR, Liu XP, Li JW: Clinical characteristics of vulvovaginal candidiasis and antifungal susceptibilities of Candida species isolates among patients in southern China from 2003 to 2006. J Obstet Gynaecol Res 2008, 34:561–566.CrossRefPubMedGoogle Scholar
  7. 7.
    Ahmad N, Khan AU: Prevalence of Candida species and potential risk factors for vulvovaginal candidiasis in Aligarh, India. Eur J Obstet Gynecol Reprod Biol 2009, 144:68–71.CrossRefPubMedGoogle Scholar
  8. 8.
    Hettiarachchi N, Ashbee HR, Wilson JD: Prevalence and management of non-albicans vaginal candidiasis. Sex Trans Infect 2010, 86:99–100.CrossRefGoogle Scholar
  9. 9.
    Agatensi L, Franchi F, Mondello F, et al.: Vaginopathic and proteolytic Candida species in outpatients attending a gynaecology clinic. J Clin Pathol 1991, 44:826–830.CrossRefPubMedGoogle Scholar
  10. 10.
    • Dennerstein GJ, Ellis DE, Reed CS, Bennett CM: The pathogenicity of non-albicans yeasts in the vagina. J Low Genit Tract Dis 2010 (in press). The authors provide convincing evidence that not all NAC infections require therapy.Google Scholar
  11. 11.
    Singh S, Sobel JD, Bhargava P, et al.: Vaginitis due to Candida krusei: epidemiology, clinical aspects, and therapy. Clin Infect Dis 2002, 35:1066–1070.CrossRefPubMedGoogle Scholar
  12. 12.
    Sobel JD, Chaim W, Nagappan V, Leaman D: Treatment of vaginitis caused by Candida glabrata: use of topical boric acid and flucytosine. Am J Obstet Gynecol 2003, 189:1297–1300.CrossRefPubMedGoogle Scholar
  13. 13.
    Richter SS, Galask RP, Messer SA, et al.: Antifungal susceptibilities of Candida species causing vulvovaginitis and epidemiology of recurrent cases. J Clin Microbiol 2005, 43:2155–2162.CrossRefPubMedGoogle Scholar
  14. 14.
    Sobel JD: Management of infections caused by Candida glabrata. Curr Infect Dis Rep 2000, 2:424–428.CrossRefPubMedGoogle Scholar
  15. 15.
    Pfaller MA, Diekema DJ, Gibbs DL, et al.; Global Antifungal Surveillance Group: Geographic variation in the frequency of isolation and fluconazole and voriconazole susceptibilities of Candida glabrata: an assessment from the ARTEMIS DISK Global Antifungal Surveillance Program. Diagn Microbiol Infect Dis 2010, 67:162–171.CrossRefPubMedGoogle Scholar
  16. 16.
    Nyirjesy P, Alexander AB, Weitz MV: Vaginal Candida parapsilosis: pathogen or bystander? Infect Dis Obstet Gynecol 2005, 13:37–41.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  1. 1.Division of Infectious DiseasesWayne State University School of MedicineDetroitUSA
  2. 2.Division of Infectious DiseasesHarper University HospitalDetroitUSA

Personalised recommendations